A phase IB open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate resistant prostate cancer (CRPC)
- Parakh, Sagun (Primary Chief Investigator (PCI))
Project: Research